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Abstract 
Direct oral anticoagulants provide an alternative to vitamin K antagonists for the anticoagulation 
therapy in atrial fibrillation (AF). The availability of several treatment options with different attributes 
makes shared decision making appropriate for the choice of anticoagulation therapy. The aim of this 
study was to understand how physicians choose an oral anticoagulant (OAC) for patients with AF and 
how physicians view patients’ participation in this decision. Semi-structured interviews with 17 
Finnish physicians (8 general practitioners and 9 specialists) working in the public sector were 
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conducted. An interview guide on experience, prescribing and opinions about oral anticoagulants was 
developed based on previous literature. The data were thematically analysed using deductive and 
inductive approaches. Based on the interviews, patient’s opinion was the most influential factor in 
decision making when there were no clinical factors limiting the choice between OACs. Of patient’s 
preferences, the most important was the attitude towards co-payments of OACs. Patients’ opinions on 
monitoring of treatment, dosing and antidote availability were also mentioned by the interviewees. 
The choice of an OAC in AF was patient-centered as all interviewees expressed that patient’s opinion 
affect the choice. 
 
Introduction 
Atrial fibrillation (AF), the most common cardiac arrhythmia, is associated with a two-fold increase in 
stroke risk [1]. In the European Union, the number of individuals aged 55 years and older with AF is 
expected to more than double from 2010 to 2060 [2]. While vitamin K antagonists (VKAs), warfarin 
in particular, have been the mainstay of anticoagulation therapy in AF, direct oral anticoagulants 
(DOACs) rivaroxaban, dabigatran, apixaban and edoxaban now provide an alternative [3-6]. In fact, 
current European guidelines recommend the use of DOACs for eligible AF patients in preference to 
VKAs [1]. Besides their fixed dosing without the need of regular laboratory monitoring, DOACs have 
a favourable risk-benefit profile, including a lower risk of intracranial haemorrhage, compared to 
warfarin [7]. 
 
The European guidelines on management of AF recommend considering patients’ preferences when 
making treatment decisions about, for example, medications [1]. In shared decision making, patients’ 
preferences are taken into account, and the treatment decision is consensual between the patient and 
the physician [8]. Shared decision making is considered appropriate for stroke prevention in AF 
because of the availability of several treatment options with different risk-benefit profiles. Recent 
physician surveys and interviews suggest that physicians consider patient participation in decision 
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making on the use of oral anticoagulants (OACs) in AF important [9-12]. Physicians also report 
clinical characteristics of the patient [13], risk of adverse events [11], their own knowledge, 
experience [10] and preferences [14] to be important in decision making. Database studies have 
identified mainly clinical factors, such as estimated stroke risk [15,16], age [16-19] and other 
cardiovascular diseases [16,17,19-21] as factors affecting the choice of an OAC. These studies have 
also found lower socioeconomic status [18-20] and poorer medication coverage [15,21] to favour the 
use of VKAs. 
 
There is no information on how patients participate in the decision making on OACs in Finland where 
the setting is different to many other countries. For example, the Finnish guidelines do not prefer use 
of DOACs over VKAs but in most cases recommend patient-specific selection between the types of 
OACs [22]. We conducted a qualitative study among Finnish physicians in primary and specialized 
health care working in the public sector to better understand the factors affecting physicians’ choice of 
an OAC in AF after the treatment decision has been made. We have previously reported results on the 
effect of clinical and non-clinical factors (e.g., need of cardioversion, contraindications, renal 
function, co-payments) on the choice of an OAC [23]. In this paper, we focus on the participation of 
patients in this choice as perceived by physicians. 
 
Methods 
Context. In Finland, the current clinical guidelines recommend patient-specific selection between 
warfarin (the only VKA available in Finland) and DOACs in AF to be based on the evaluation of 
medications’ properties and the patient’s opinion [22]. DOACs are preferred if anticoagulation is 
needed only for short-term (e.g., for cardioversion). Among the disadvantages of DOACs, the 
guideline lists the lack of a specific antidote for other DOACs than dabigatran. Also, the cost of 
DOACs is among the disadvantages. At the time of the interviews (November 2016-February 2017), 
the difference in the monthly cost shared by the patient between warfarin and DOACs was nearly €50 
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(only small cost differences between DOACs). In addition, not all patients with AF were entitled to 
the reimbursement for DOACs, increasing the difference to almost €90. The quality of warfarin 
treatment, measured as time in therapeutic range, has been reported to be good in Finland compared to 
many non-Nordic countries [24,25]. 
 
In addition to the regulatory monitoring of pharmaceutical marketing, the pharmaceutical industry 
self-regulates its marketing in Finland [26]. It is forbidden to offer physicians any financial incentives, 
including promotional gifts related to prescription-only medications. Training and medical 
representations by the pharmaceutical industry are also regulated. No incentives for prescribing 
certain medications or managing chronic illnesses are offered by the public healthcare system either. 
 
Sampling, recruitment and data collection. Using purposive sampling, we recruited participants from 
12 primary health care organizers with and without anticoagulation clinics and 13 clinics in six special 
healthcare hospitals in Central and Eastern Finland. Physicians were recruited by email personally or 
through administration, chief physicians, medical directors or contact persons named by the 
organizations. Recruitment continued until data saturation [27] (i.e., after no new themes emerged in 
interviews). The study included physicians who were working in primary or specialized healthcare 
(cardiology, neurology and internal medicine) in the public sector and were willing to participate in 
the study. The three medical specialties were chosen because they typically treat patients with AF. 
 
Data were collected through semi-structured interviews [28]. We developed an interview guide with 
open-ended questions based on previous literature [9,10,12-14] (Supporting information). The guide 
was pretested in three pilot interviews that were not included in the data. The interviewer also asked 
follow-up questions prompted by participant’s responses, and points outside the guide were discussed 
if introduced by the participant. Interviews were recorded with participants’ permission and 
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transcribed verbatim by an independent transcription service. One researcher (EA) conducted all 
interviews. 
 
In total, 13 face-to-face interviews at physicians’ work places and four phone interviews (25–65 min. 
each) were conducted. The sample included eight general practitioners (GPs) from seven primary 
healthcare organizers and nine specialists (two from neurology, five from cardiology and two from 
internal medicine) from six hospitals (Table 1). Three GPs worked in an organization with an 
anticoagulation clinic. 
 
The interviewees had practiced medicine from less than a year to >30 years (Table 1). In addition, the 
extent of experience with DOACs varied across the physicians from writing only a few DOAC 
prescriptions to prescribing them weekly. At the time of the interviews, none of the interviewees had 
prescribed edoxaban. 
 
Data analysis. One researcher (EA) compared the transcripts of the interviews with the recordings and 
analysed de-identified data to find factors affecting the choice of an OAC. The data were thematically 
analysed using both deductive and inductive approaches [29]. In deductive approach, factors 
previously reported to affect the choice were looked for in the data (e.g., co-payment, monitoring and 
patients’ preferences). In inductive approach, the data were searched to find new influential factors. 
The new factors found inductively included indication (the need for cardioversion in particular), 
physicians’ past OAC prescribing habits, characteristics of clinical trials, and patients’ entitlement to 
reimbursement affecting the amount of co-payment. 
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Ethics and consent statement. The study complied with the national ethical principles of research [30]. 
According to the instructions, this study did not require ethical approval. Willingness to participate in 
the interviews was seen as a consent to participate in the study. 
 
Results 
Based on the interviews, when there were no contraindications or other clinical factors limiting the 
choice between OACs (e.g., renal function, interactions with co-medication), patient’s opinion was 
the most influential factor. There were no great differences between the interviewed GPs and 
specialists in the effect of patients’ preferences on the decision making, overall, and all the 
interviewees expressed that patients’ opinions affect the choice. When physicians were asked 
generally about prescribing of OACs and the process of choosing an OAC, all but two physicians 
mentioned patient participation in the decision making unprompted. In addition, when asked which 
factors ease the choice between OACs, six physicians mentioned patients’ opinion. 
 
“Perhaps you do to steer the conversation into a specific direction. Even if there aren’t any 
contraindications, there are still arguments that support one way over the other. Well, there’s the 40-
year-old relatively healthy man who has no risk of bleeding. In that case, the patient gets to choose 
whether he wants to take medication once or twice a day.” (S04, cardiology) 
 
Of patients’ preferences, the most important was their views about the co-payment of OACs (Table 
2). All the interviewees said that DOACs are too expensive for some patients for whom the co-
payment is the deciding factor. Even though some of the interviewees had strong preferences for 
DOACs, they prescribed warfarin if the patient considered DOACs too expensive. 
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“If it’s a question of price, the choice is made in favour [of warfarin].” (GP08) 
 
Patients’ attitude towards the monitoring of warfarin treatment was mentioned in ten interviews 
(Table 2). According to the interviewees, some patients want to use DOACs because they find regular 
monitoring of international normalized ratio (INR) inconvenient. Patients may also experience 
difficulties in having their INR controlled due to long distances (e.g., for not owning a car), poor 
health (going to INR tests constitutes a burden) or employment (difficulties combining work and 
going to INR tests, work-related travels). However, not all patients view INR monitoring as a negative 
attribute. 
 
“INR tests are not a problem for every patient. It might even be the other way around. Then a taxi 
bringing you to the town center is the highlight of the week or month. It gives the patient the chance to 
go shopping and see other people.” (S06, cardiology) 
 
Besides preferences affecting the choice between warfarin and DOACs, some interviewees mentioned 
patients’ preferences that can affect the choice between different DOACs (Table 2). Ten interviewees 
said they took into account patients’ opinion about the dosing frequency (i.e., taken once or twice a 
day). In addition, six interviewees told patients may wish to be prescribed a DOAC with a specific 
antidote available. However, there were differences between the interviewees whether they offered all 
DOACs to patients or chose which DOAC to offer alongside warfarin. 
 
“Some go for [a medication taken] once a day. Then again, some opt specifically for a medication 
with an existing antidote.” (S03, neurology) 
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Based on the interviews, the most common reason why physicians included patients in the decision 
making was the large difference in the co-payments between warfarin and DOACs. All interviewees 
mentioned the importance of co-payment to some patients, and a few physicians mentioned especially 
that they prescribe each patient an OAC the patient can afford to use. In addition, three physicians felt 
that patients adhere better to their treatment when they have participated in the decision making. 
 
Another reason why patient preferences are so influential might be that the different OACs were 
viewed equally effective: 11 physicians considered high quality warfarin treatment as effective as 
DOACs, although 11 physicians felt DOACs to be safer than warfarin. In addition, 10 physicians 
mentioned that they did not see great differences between different DOACs or that they have not been 
directly compared and, therefore, none of them can be said to be better than the others. However, 
some physicians expressed they preferred a specific anticoagulant in some situations and in those 
cases they tried to steer the conversation towards their choice or offer only one or some of the DOACs 
to the patient. 
 
Even though our main focus was on the initiation of OAC treatment, the interviewees were also asked 
about switching of OACs. The influence of patients’ opinions was evident also in these responses: the 
most frequently reported reasons for switching were patient request in addition to poor quality of 
warfarin therapy. Thirteen physicians told that they had switched patients from warfarin to a DOAC 
because patients, for example, found DOACs easier to administer or INR monitoring inconvenient 
(Table 2). Seven interviewees had switched patients from a DOAC to warfarin, mainly due to the high 
co-payment of DOACs. 
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Discussion 
Based on the 17 interviews conducted in our study, the choice of an OAC in AF is patient-centered, 
particularly when choosing between warfarin and a DOAC, and the patient’s preferences strongly 
affect the decision making if there are no contraindications or other clinical factors limiting the 
choice. According to the interviewed physicians, warfarin’s markedly lower co-payment is a deciding 
factor for some patients. In addition, patients may have preferences regarding the dosing frequency or 
availability of a specific antidote regarding DOACs. The main reason for physicians to involve the 
patient in the decision making seems to be to enhance treatment success. 
 
Our findings on the importance of patients’ opinions accord with recent studies on decision making on 
anticoagulation therapy in AF. In their study, Kirley et al. interviewed physicians about decision 
making on anticoagulation management in patients with AF in general [10]. Patient convenience and 
preferences were found to be important to physicians when considering anticoagulation. In addition, 
co-payment emerged as an important barrier to DOAC use. In another US study, physicians from a 
single medical centre were surveyed about factors influencing their choice between warfarin and 
dabigatran for patients with AF [13]. Patient request was the third most common reason, after factors 
related to patient convenience, to prescribe dabigatran to patients without a previous OAC and the 
fourth most common reason among patients using warfarin after factors related to patient convenience 
and unstable INR. The co-payment of DOACs was important also in this study as cost was the most 
common reason for not prescribing dabigatran. 
 
Similar results about the importance of the patient’s role have been reported also from other countries. 
In a Canadian survey for internal medicine residents, patient convenience was the second most 
important factor when choosing an OAC for patients with AF after adverse events [11]. In Italy, 70% 
of internal medicine centers participating in a survey on DOACs regarded the patient’s preference to 
be highly relevant when prescribing DOAC therapy in AF [9]. In a Norwegian focus group study 
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among hospital physicians, patients’ preferences were reported to be important factors in decision 
making although patients’ characteristics were most influential factors when choosing an OAC [12].  
 
Palacio et al. reported that patients potentially exposed to a decision on anticoagulation (i.e., patients 
at risk of AF or already on OACs) prefer to take part in the decision making [31]. This accords with 
the patients’ participation described by the physicians interviewed in our study. However, in the 
survey by Choi et al., only 25% of warfarin users and 37% of dabigatran users had discussed with 
their physician about treatment options when initiating anticoagulation [32]. The preceding study was 
conducted in 2011. It is possible that patients’ participation in decision making on OACs has 
increased after more DOACs have entered the market and DOAC use has increased. 
 
Results from patient-based studies support our observations on the importance of OAC attributes 
other than the effect on stroke and bleeding risks. According to the review by Wilke et al., patients 
prefer more easily administered treatments if the treatments’ clinical effects are similar [33]. For 
example, in a German study, patients overall preferred a treatment with no requirement for INR 
monitoring or dose adjustments, no interactions with food, and once-daily dosing [34]. In a Dutch 
study, the most important reason for patients to switch to a DOAC was that frequent laboratory 
monitoring is not required [35]. However, the results on patient preferences have been mixed [36]. 
For example, patients’ attitudes towards monitoring may vary considerably [37], and some patients 
using warfarin are reluctant to switch to a DOAC because the lack of laboratory monitoring [38]. This 
accords with our interviews where physicians mentioned both patients’ negative and positive attitudes 
towards INR monitoring. In an Italian study of VKA users, the majority was worried about using a 
DOAC for which no antidote was available [38]. Accordingly, some of our interviewees brought up 
the importance of the availability of a specific antidote for some patients. As DOACs’ reimbursement 
rates have been raised in Finland after our study period causing the difference in co-payments to 
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decrease for patients entitled to reimbursement [39], it is possible that the importance of these OAC 
attributes has increased in decision making. 
 
Patients’ differing preferences reported in previous studies [36-38] and in our study emphasize the 
importance of shared decision making when choosing an OAC. As different patients have different 
preferences, physicians should ask their patients which attributes are important to them. Application 
of shared decision making could improve patient adherence to treatment [40]. 
  
Our study has limitations. Firstly, the number of interviewed physicians is small. However, our 
sample size is similar to that of previous qualitative studies (range 7 to 12 interviewees [10,12]). 
Furthermore, data saturation was reached. Conversely, although we reached theme saturation, we did 
not reach meaning saturation in all the themes emerging in the interviews [27]. For example, there 
was not enough evidence to draw conclusions on the association between physicians’ prescribing 
frequency and shared decision making. Larger and quantitative studies are needed to explore this and 
the generalizability of the results to physicians in Finland and elsewhere. Secondly, we did not 
conduct any interviews among patients with AF to ascertain their participation in the decision making 
about OACs. Further studies are needed to study whether patients feel that their preferences are taken 
into account by their physicians and whether this impacts their adherence. Another limitation of our 
study is that only one researcher analysed the data, although continuous discussions were done among 
the research group to reflect the findings. 
 
According to the views of the interviewed physicians, AF patients participate in the choice of their 
OAC. The interviewed physicians took into consideration patients’ preferences in particular when 
choosing between warfarin and a DOAC. This was mainly due to the difference in the costs of these 
medications shared by the patient but also to patients’ preferences regarding INR monitoring. When 
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choosing between DOACs, some physicians also took into account patients’ preferences on dosing 
frequency and availability of a specific antidote. The main reason for considering patients’ 
preferences was to enhance the success of treatment. 
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Table 1. Characteristics of the 17 physicians 
Characteristic n 
Sex  
Male 14 
Female 3 
Working years  
Less than 5 years 6 
5–10 years 2 
11–20 years 2 
Over 20 years 7 
Speciality  
Cardiology 5* 
Neurology 2 
Internal medicine 2 
General medicine 3 
None 5 
Frequency of treating patients with AF  
Daily 11 
Weekly 5 
Monthly 0 
Less than monthly 1 
*2 of 5 were specialists in cardiology and internal medicine 
AF: atrial fibrillation 
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Table 2. Patient preferences affecting the oral anticoagulant choice mentioned by the 17 physicians 
Preferences n 
When initiating treatment  
Co-payments 17 
Need for treatment monitoring 10 
Dosing 10 
Availability of an antidote 6 
When switching treatment  
Co-payments 7 
Need for treatment monitoring  4 
Convenience of treatment 4 
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